All News

male female

Do different genders experience PsA differently?

d Olga Petryna, MD

There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease.  Are the differences only cultural or are there important clinical differences in the disease presentation, organ involvement and complications that physicians should be aware of?   

Read Article
dumbbells-2465478_640.jpg

Is exercise the missing medicine in lupus?

d Eric Dein, MD

For lupus, sedentary lifestyle may be a driving force of disease activity.  Today, the final day of ACR, Sarah Patterson, MD from UCSF will present

Read Article
800+ women w/ IMID & 1700+ ctrl w/ 6 yrs follow-up All GC users < BMD levels -4.2% > 2.5mg/d -2.7% <2.5mg/d Crude FX rate 4.8/100PY GC >= 5mg/d, 2.5/100PY GC < 2.5mg/d 🦴Fx incidence > IMID vs. Ctrls GC use >= 5mg/d x2 risk of Fx https://t.co/6sj77PwyYQ Abs#L01 #ACR22 @Rheumnow https://t.co/OZhfuh0Jrm

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴 Reminder: Recalculate FRAX scores with scaling for prednisone equivalent dosing! Use other clinical fracture risk assessments @RheumNow https://t.co/qZDlb1Cij7
Eric Dein ericdeinmd ( View Tweet)
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: FRAX needs to be adjusted according to the dose of GC's (7.5+ mg/day multiply FRAX score by 1.2) #ACR22 @rheumnow https://t.co/U7IOjbTwxN
TheDaoIndex KDAO2011 ( View Tweet)
#L01 #acr22 @rheumnow chronic GC use in rheum Dx assoctd w/⬇️ T scores & ⬆️fracture even if dose 2.5 mg or less. GC use ≥5 mg/day associated w/ 2-fold higher risk of fracture of any kind compared to all other doses& controls (aHR 2.37, 95% CI 1.33-4.23).Preventable w/anti-OP Rx https://t.co/sCWkEBPMMT
Olga Petryna DrPetryna ( View Tweet)
Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increase in disease activity (to same level as prev placebo), numerical increase in flare. No adrenal insufficiency @RheumNow #ACR22 Abstr#2000 https://t.co/5oclSdlXWA https://t.co/HT2pmsxPiC

Links:

Richard Conway RichardPAConway ( View Tweet)
Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual care in low-moderate disease activity RA. It worked! But which of the 3 parts of the intervention was responsible? @RheumNow #ACR22 Abstr#1998 https://t.co/X1f07ZWPjU https://t.co/nkM4misfFW

Links:

Richard Conway RichardPAConway ( View Tweet)
Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #ACR22 Abstr#1757 https://t.co/Ft3Km8Jw17 https://t.co/uBOUnV4n0Z

Links:

Richard Conway RichardPAConway ( View Tweet)
Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @RheumNow #ACR22 Abstr#1833 https://t.co/9dOlfYMVlj https://t.co/a3uvw3gVw3

Links:

Richard Conway RichardPAConway ( View Tweet)
Kivitz et al. Phase 2 RCT Dazodalibep (non-antibody biologic antagonist of CD40L) in csDMARD/bDMARD-IR RA. Improve DAS28-CRP, CDAI, SDAI, TJC, SJC at day 113. @RheumNow #ACR22 Abstr#2008 https://t.co/RwRbeFC4rt https://t.co/F8bEI1lZGM

Links:

Richard Conway RichardPAConway ( View Tweet)
L09 #ACR22 MTX in Post-Roe Era 6% patients reported barrier to MTX access 1 pt noted restriction to HCQ Most delays due to pharmacy - told due to pregnancy/abortion concerns or unexplained reason Rare BUT Real Problem - shows importance of @ACRheumDC advocacy efforts @RheumNow https://t.co/8Yr7nynzN6
Eric Dein ericdeinmd ( View Tweet)
L10 #ACR22 Efgartigimod in IMNM IgG1 Fc fragment targeting neonatal Fc receptor (FcRn) Restored grip and muscle strength in mice studies with pathogenic anti-HMGCR+ (p<0.05) Total IgG and anti-HMGCR Ab became undetectable @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p

Links:

Richard Conway RichardPAConway ( View Tweet)
Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW

Links:

Richard Conway RichardPAConway ( View Tweet)
Gurwith et al ABP-671 a URAT1 inhibitor effectively lowers serum urate @RheumNow #ACR22 Abstr#1822 https://t.co/hXAQoVHrLH https://t.co/saVqu4kbnr

Links:

Richard Conway RichardPAConway ( View Tweet)
L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure. AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%) @RheumNow https://t.co/G31PrfqtVu
Eric Dein ericdeinmd ( View Tweet)
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS P3b: SEC 150 mg v SEC 300 v SDZ-ADL Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance Hard to assess as overall, low rate of progression @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Lindegren et al. Dairy intake and RA risk in Sweden. Nested case-control. High regular milk intake assoc increased risk (OR 1.90) High cheese assoc decresaed risk (OR 0.52) @RheumNow #ACR22 Abstr#1758 https://t.co/jUz3SJBf4Y https://t.co/ZykW3NjSrK

Links:

Richard Conway RichardPAConway ( View Tweet)
A spicy result. say NO to turmeric in #rheumatoidarthritis Eat it on food, but don’t expect it to help your joints. @RheumNow #ACR22 https://t.co/1mZBm3rYAA

Links:

Janet Pope Janetbirdope ( View Tweet)

×